← FDA DRUG APPROVALS

FDA ANDA · ANDA213074

NEOSTIGMINE METHYLSULFATE

Sponsor: CAPLIN

APPLICATION
ANDA213074
TYPE
ANDA
ORIGINAL APPROVAL
2021-04-20
LATEST ACTION
2021-04-20
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

NEOSTIGMINE METHYLSULFATEPrescription
NEOSTIGMINE METHYLSULFATE 10MG/10ML (1MG/ML) · SOLUTION · INTRAVENOUS
NEOSTIGMINE METHYLSULFATEPrescription
NEOSTIGMINE METHYLSULFATE 5MG/10ML (0.5MG/ML) · SOLUTION · INTRAVENOUS

Approval history

2021-04-20UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →